Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer

被引：0
|
作者：
S. H. Waters
A. Gillibrand
H. Berry
S. Kumar
G. Velikova
D. J. Dodwell
Timothy J. Perren
机构：
[1] St James’s Institute of Oncology,
来源：
Cancer Chemotherapy and Pharmacology | 2009年 / 64卷
关键词：
Anthracyclines; Antineoplastic combined chemotherapy protocols; Breast neoplasms; Capecitabine; Taxoids;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：407 / 412
页数：5
相关论文
共 50 条
  • [41] Sequential docetaxel followed by epirubicin-vinorelbine as first-line chemotherapy in advanced breast cancer
    Vici, P
    Foggi, P
    Colucci, G
    Capomolla, E
    Brandi, M
    Giotta, F
    Gebbia, N
    Di Lauro, L
    Valerio, MR
    Paoletti, G
    Belli, F
    Pizza, C
    Giannarelli, D
    Lopez, M
    ANTICANCER RESEARCH, 2005, 25 (2B) : 1309 - 1314
  • [42] Phase II study of weekly epirubicin and docetaxel as first line chemotherapy in metastatic breast cancer
    Gamucci, Teresa
    D'Ottavio, Anna Maria
    Gareri, Roberta
    Vaccaro, Angela
    Belli, Franca
    Nunziata, Corrado
    Meliffi, Loretta
    Moscetti, Luca
    Barduagni, Mario
    Sperduti, Isabella
    ANNALS OF ONCOLOGY, 2004, 15 : 48 - 49
  • [43] Low dose sequential docetaxel-capecitabine chemotherapy as first-line treatment of metastatic breast cancer (mbc)
    Hafeez, M.
    Shaharyar, A.
    Masood, A. I.
    Zikria, M.
    Usman, A.
    Shabbir, K.
    Nadeem, Z.
    Tahir, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients
    Venturini, M
    Michelotti, A
    Papaldo, P
    Del Mastro, L
    Bergaglio, M
    Lionetto, R
    Lunardi, G
    Sguotti, C
    Frevola, L
    Donati, S
    Rosso, R
    Cognetti, F
    ANNALS OF ONCOLOGY, 2001, 12 (08) : 1097 - 1106
  • [45] A phase II study of weekly low-dose docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer
    Chen, J. S.
    Shen, W. C.
    Chen, Y. Y.
    Huang, J. S.
    Yeh, K. Y.
    Chen, P. T.
    Hsu, H. C.
    Lin, Y. C.
    Wang, H. M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 375 - 376
  • [46] Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
    Zarate, R.
    Rodriguez, J.
    Bandres, E.
    Patino-Garcia, A.
    Ponz-Sarvise, M.
    Viudez, A.
    Ramirez, N.
    Bitarte, N.
    Chopitea, A.
    Gacia-Foncillas, J.
    BRITISH JOURNAL OF CANCER, 2010, 102 (06) : 987 - 994
  • [47] Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
    R Zarate
    J Rodríguez
    E Bandres
    A Patiño-Garcia
    M Ponz-Sarvise
    A Viudez
    N Ramirez
    N Bitarte
    A Chopitea
    J Gacía-Foncillas
    British Journal of Cancer, 2010, 102 : 987 - 994
  • [48] Doxorubicin (Dox), cyclophosphamide (Cyc) and weekly docetaxel (Doc) as first-line treatment of advanced breast cancer (ABC)
    Ibrahim, T.
    Serra, P.
    Vertogen, B.
    Marangolo, M.
    Amadori, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [49] A PHASE I DOSE-FINDING STUDY OF VORINOSTAT (V) COMBINED WITH CAPECITABINE (X) AND CISPLATIN (P) AS FIRST-LINE THERAPY IN PATIENTS WITH ADVANCED GASTRIC CANCER
    Yoo, C.
    Ryu, M. H.
    Ryoo, B.
    Koo, D. H.
    Park, I.
    Kang, Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 234 - 234
  • [50] Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer
    Polyzos, A
    Tsavaris, N
    Kosmas, C
    Gogas, H
    Vadiaka, M
    Markopoulos, C
    Giannopoulos, A
    Kalahanis, N
    Stamatiadis, D
    Kouraklis, G
    Karatzas, G
    Liapis, C
    Syrigos, K
    ANTICANCER RESEARCH, 2003, 23 (3C) : 2917 - 2923
12345